Gitnux/Report 2026

Pharmaceutical Statistics

With the FDA still moving fast, 55 new drugs were approved in 2023 alongside 38 EMA medicines, while oncology led the pace with 14 FDA approvals. The page connects global R and D, market size reaching $1.48 trillion in 2023, and major pharma spend at scale to explain why innovation pipelines, workforces, and revenues are shifting in real time.
127Statistics
5Sections
1Visuals
8mRead
12 days agoUpdated
Pharmaceutical Statistics
Verified via a 4-step process
01Source

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Verify

Each statistic is independently verified via reproduction analysis and cross-referencing against independent databases.

03Grade

Figures are graded by cross-model consensus. Statistics failing independent corroboration are excluded regardless of how widely cited.

04Cite

Every figure carries a primary source. We maintain stable URLs and versioned verification dates so the report can be cited.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Next review Jan 2027
In 2023, the global pharmaceutical market hit $1.48 trillion, while R&D investment reached $200 billion and yet approval pipelines moved at very different speeds across regulators and regions. The contrast is striking too, with the FDA approving 55 new drugs and the EMA approving 38, alongside 14 new FDA oncology approvals and 103 novel drugs cleared globally. This post pulls these figures into one view to show what the numbers suggest about innovation, workforce scale, and where growth is concentrating.

Key Takeaways

  • FDA approved 55 new drugs in 2023
  • EMA approved 38 new medicines in 2023
  • 103 novel drugs approved globally in 2023
  • Pharma industry employs 5.5 million people globally in 2023
  • U.S. pharma manufacturing jobs: 300,000 in 2023
  • India pharma sector employs 3 million people in 2023
  • Global pharmaceutical market size reached $1.48 trillion in 2023
  • U.S. pharmaceutical market accounted for 45% of global sales in 2022
  • Pharmaceutical market in Europe was valued at $370 billion in 2023
  • Global R&D spending by pharma industry was $200 billion in 2022
  • Pfizer R&D expenditure $10.8 billion in 2023
  • Roche R&D spend CHF 15.2 billion in 2023
  • Pfizer generated $58.5 billion in revenue in 2023
  • Johnson & Johnson pharma sales $54.1 billion in 2023
  • Roche total revenue CHF 65.4 billion in 2023

In 2023, global drug approvals and spending surged alongside a $1.48 trillion market and rising R&D investment.

01 · Category

Drug Approvals And Pipelines19 stats

01
FDA approved 55 new drugs in 2023
02
EMA approved 38 new medicines in 2023
03
103 novel drugs approved globally in 2023
04
Oncology drugs: 14 new FDA approvals in 2023
05
Gene therapies: 5 FDA approvals in 2023
06
First CRISPR therapy (Casgevy) approved by FDA in 2023
07
Biologics approvals: 17 by FDA in 2023
08
Orphan drugs: 24 FDA approvals in 2023
09
Pfizer had 5 new drug approvals in 2023
10
Merck 3 new approvals including new indications in 2023
11
Global clinical trials: 350,000 in pharma pipeline 2023
12
Phase III trials: 1,200 active in pharma 2023
13
Oncology pipeline: 1,800 drugs in development 2023
14
Alzheimer's pipeline: 140 drugs in 2023
15
mRNA vaccines pipeline: 50+ candidates 2023
16
Biosimilars approvals: 10 by FDA in 2023
17
CAR-T therapies: 1,000 in pipeline globally 2023
18
Rare disease drugs pipeline: 2,000+ 2023
19
ADC (antibody-drug conjugates) pipeline: 240 molecules 2023
Interpretation

Drug Approvals And Pipelines Interpretation

In the Drug Approvals and Pipelines landscape, 103 novel drugs gained global approval in 2023 alongside 55 new FDA approvals, signaling a strong and sustained momentum in bringing both oncology advances and gene therapies to market, including 5 FDA gene-therapy approvals and the first CRISPR therapy Casgevy.

02 · Category

Employment And Operations23 stats

01
Pharma industry employs 5.5 million people globally in 2023
02
U.S. pharma manufacturing jobs: 300,000 in 2023
03
India pharma sector employs 3 million people in 2023
04
Europe pharma workforce 800,000 in 2023
05
China pharma employees 2 million in 2023
06
R&D staff in global pharma: 1 million scientists 2023
07
Women represent 45% of pharma workforce globally 2023
08
Manufacturing jobs grew 2% in pharma 2023
09
Contract research organizations (CRO) employ 400,000 2023
10
Biotech startups employ 300,000 globally 2023
11
Pharma sales reps: 500,000 worldwide 2023
12
Supply chain roles in pharma: 1.2 million 2023
13
Regulatory affairs professionals: 100,000 globally 2023
14
Pharmacovigilance staff: 150,000 in 2023
15
Digital health roles in pharma grew 15% to 200,000 in 2023
16
Pfizer workforce 88,000 employees in 2023
17
J&J pharma division 50,000 employees 2023
18
Roche 103,000 employees in 2023
19
Novartis 101,000 staff in 2023
20
Sanofi 86,000 employees 2023
21
AstraZeneca 89,900 employees in 2023
22
Merck & Co. 70,000 employees 2023
23
GSK 70,000 employees post-restructuring 2023
Interpretation

Employment And Operations Interpretation

In the Employment And Operations landscape, global pharma supported 5.5 million jobs in 2023, with major staffing hubs including India’s 3 million workers, China’s 2 million employees, and the US adding 300,000 manufacturing jobs.

03 · Category

Market Size And Growth30 stats

01
Global pharmaceutical market size reached $1.48 trillion in 2023
02
U.S. pharmaceutical market accounted for 45% of global sales in 2022
03
Pharmaceutical market in Europe was valued at $370 billion in 2023
04
Asia-Pacific pharma market grew at 7.2% CAGR from 2018-2023
05
Biopharmaceuticals segment expected to grow to $650 billion by 2028
06
Generic drugs market size hit $465 billion globally in 2022
07
OTC pharmaceuticals market valued at $183 billion in 2023
08
Pharma market in China reached $170 billion in 2023
09
Latin America pharma market projected to reach $140 billion by 2027
10
Middle East & Africa pharma market grew 5.8% in 2023
11
Global pharma market CAGR forecasted at 6.1% through 2030
12
U.S. retail pharma sales $600 billion in 2023
13
Indian pharma market size $50 billion in FY2023
14
Japanese pharma market valued at $110 billion in 2023
15
Brazilian pharma market $35 billion in 2023
16
South Korean pharma market grew 4.5% to $25 billion in 2023
17
Australian pharma market $12 billion in 2023
18
Canadian pharma market $35 billion CAD in 2023
19
German pharma market €60 billion in 2023
20
French pharma market €52 billion in 2023
21
UK pharma market £25 billion in 2023
22
Russian pharma market $30 billion in 2023
23
Turkish pharma market $8 billion in 2023
24
Pharma market in Saudi Arabia $7 billion in 2023
25
UAE pharma market $5.5 billion in 2023
26
Pharma e-commerce market $25 billion globally in 2023
27
Contract manufacturing in pharma $150 billion in 2023
28
Radiopharmaceuticals market $6 billion in 2023
29
Nutraceuticals market $450 billion in 2023
30
Global pharma logistics market $100 billion in 2023
Interpretation

Market Size And Growth Interpretation

The pharmaceutical market is expanding strongly, growing to $1.48 trillion globally in 2023 while Asia Pacific posts 7.2% CAGR from 2018 to 2023 and biopharmaceuticals are projected to reach $650 billion by 2028, underscoring robust market size and growth momentum.

04 · Category

R&d Spending25 stats

01
Global R&D spending by pharma industry was $200 billion in 2022
02
Pfizer R&D expenditure $10.8 billion in 2023
03
Roche R&D spend CHF 15.2 billion in 2023
04
Merck & Co. R&D $30.5 billion in 2023 (incl. acquisitions)
05
Johnson & Johnson R&D $15.1 billion in 2023
06
Novartis R&D CHF 10 billion in 2023
07
AstraZeneca R&D $10.5 billion in 2023
08
Sanofi R&D €7 billion in 2023
09
Bristol Myers Squibb R&D $9.3 billion in 2023
10
AbbVie R&D $6.5 billion in 2023
11
GSK R&D £5.7 billion in 2023
12
Eli Lilly R&D $9 billion in 2023
13
Novo Nordisk R&D DKK 28.2 billion in 2023
14
Amgen R&D $4.7 billion in 2023
15
Gilead R&D $5.1 billion in 2023
16
Biogen R&D $3.3 billion in 2023
17
Moderna R&D $4.8 billion in 2023
18
Regeneron R&D $4.3 billion in 2023
19
Vertex R&D $2.8 billion in 2023
20
Pharma R&D as % of sales averaged 20% in 2023
21
Oncology R&D investment $80 billion in 2023
22
Gene therapy R&D spend $5 billion in 2023
23
mRNA tech R&D $10 billion across companies in 2023
24
AI in pharma R&D investment $2 billion in 2023
25
Cell therapy R&D $4 billion in 2023
Interpretation

R&d Spending Interpretation

In the R&D spending category, the pharma industry’s global spend reached $200 billion in 2022, while major players like Merck rose to $30.5 billion in 2023 and Pfizer invested $10.8 billion the same year, underscoring how heavily companies continue to fund innovation at massive scales.

05 · Category

Revenue And Sales30 stats

01
Pfizer generated $58.5 billion in revenue in 2023
02
Johnson & Johnson pharma sales $54.1 billion in 2023
03
Roche total revenue CHF 65.4 billion in 2023
04
Merck & Co. sales $60.1 billion in 2023
05
AbbVie revenue $54.3 billion in 2023
06
AstraZeneca revenue $45.8 billion in 2023
07
Novartis revenue $45.4 billion in 2023
08
Sanofi sales €43.4 billion in 2023
09
Bristol Myers Squibb revenue $45 billion in 2023
10
GSK revenue £30.3 billion in 2023
11
Eli Lilly sales $34.1 billion in 2023
12
Novo Nordisk revenue DKK 232.3 billion in 2023
13
Amgen revenue $28.2 billion in 2023
14
Gilead Sciences revenue $27.1 billion in 2023
15
Vertex Pharmaceuticals revenue $9.9 billion in 2023
16
Regeneron revenue $13 billion in 2023
17
Moderna revenue $6.8 billion in 2023
18
BioNTech revenue €4.1 billion in 2023
19
Top 10 pharma companies generated 40% of global industry revenue in 2023
20
Oncology drugs generated $200 billion in global sales in 2023
21
Diabetes drugs sales reached $60 billion globally in 2023
22
Cardiovascular drugs revenue $140 billion in 2023
23
Immunology drugs sales $120 billion in 2023
24
Keytruda (Merck) sales $25 billion in 2023
25
Humira (AbbVie) sales $14.4 billion in 2023
26
Ozempic (Novo Nordisk) sales $13.9 billion in 2023
27
Comirnaty (Pfizer/BioNTech) sales $11.2 billion in 2023
28
Stelara (J&J) sales $10.9 billion in 2023
29
Eliquis (BMS/Pfizer) sales $12.2 billion in 2023
30
Opdivo (BMS) sales $9 billion in 2023
Interpretation

Revenue And Sales Interpretation

In the Revenue And Sales category, the top pharmaceutical players reported remarkably similar 2023 figures, with Pfizer at $58.5 billion and Merck & Co. at $60.1 billion sitting close to AbbVie at $54.3 billion and Johnson & Johnson at $54.1 billion, while Roche led at CHF 65.4 billion and AstraZeneca followed with $45.8 billion.
report visual · Comparison

2023 Pharmaceutical approvals: U.S. vs global

In 2023, the FDA approved dozens of new drugs while global approvals totaled over a hundred, with notable concentration in oncology and emerging areas like gene therapy.

103 novel drugs approved globally in 2023103
FDA approved 55 new drugs in 2023
55
Oncology drugs: 14 new FDA approvals in 2023
14
Gene therapies: 5 FDA approvals in 2023
5
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Isabelle Moreau. (2026, February 13). Pharmaceutical Statistics. Gitnux. https://gitnux.org/pharmaceutical-statistics
MLA
Isabelle Moreau. "Pharmaceutical Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pharmaceutical-statistics.
Chicago
Isabelle Moreau. 2026. "Pharmaceutical Statistics." Gitnux. https://gitnux.org/pharmaceutical-statistics.